PharmaKB logo
Company Reports
Company Reports
Drug Reports
Drug Reports
Disease Reports
Disease Reports
AboutPricing
Drug ReportsMercaptopurine
Purinethol, Xaluprine (previously mercaptopurine nova laboratories)(mercaptopurine)
Mercaptopurine, Purinethol, Purixan, Xaluprine (mercaptopurine) is a small molecule pharmaceutical. Mercaptopurine was first approved as Purinethol on 1982-01-01. It is used to treat b-cell chronic lymphocytic leukemia, non-hodgkin lymphoma, and precursor cell lymphoblastic leukemia-lymphoma in the USA. It has been approved in Europe to treat lymphoid leukemia.
Download report
Favorite
Drugs Approved for Childhood Cancers
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Plot placeholder
Mock data
Subscribe for the real data
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
hemic and lymphatic diseasesD006425
immune system diseasesD007154
signs and symptoms pathological conditionsD013568
Trade Name
FDA
EMA
Mercaptopurine, Purinethol, Purixan
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Mercaptopurine
Tradename
Company
Number
Date
Products
PURIXANNova LaboratoriesN-205919 RX2014-04-28
1 products, RLD, RS
PURINETHOLStason PharmaceuticalsN-009053 RX1982-01-01
1 products, RLD
Labels
FDA
EMA
Brand Name
Status
Last Update
mercaptopurineANDA2025-02-21
purixanNew Drug Application2024-10-25
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
L: Antineoplastic and immunomodulating agents
— L01: Antineoplastic agents
— L01B: Antimetabolites
— L01BB: Purine analogs, antimetabolites antineoplastic
— L01BB02: Mercaptopurine
HCPCS
Code
Description
S0108
Mercaptopurine, oral, 50 mg
Clinical
Clinical Trials
268 clinical trials
View more details
Plot placeholder
Mock data
Subscribe for the real data
Indications Phases 4
No data
Indications Phases 3
No data
Indications Phases 2
No data
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients———1————1
Indications Without Phase
No data
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameMercaptopurine
INNmercaptopurine
Description
Purine-6-thiol is a thiol that is the tautomer of mercaptopurine. It has a role as an antineoplastic agent and an antimetabolite. It is a tautomer of a mercaptopurine. It derives from a hydride of a 7H-purine.
Classification
Small molecule
Drug classaptamers, classical and mirror
Image (chem structure or protein)Loading
Structure (InChI/SMILES or Protein Sequence)
O.S=c1[nH]cnc2nc[nH]c12
Identifiers
PDB—
CAS-ID6112-76-1
RxCUI—
ChEMBL IDCHEMBL1200751
ChEBI ID31822
PubChem CID667490
DrugBankDB01033
UNII IDPKK6MUZ20G (ChemIDplus, GSRS)
Target
No data
Variants
No data
Financial
Revenue by drug
$
€
£
â‚£
No data
Estimated US medical usage
Mercaptopurine
Total medical expenditures per year (USD, in millions)
Plot placeholder
Mock data
Subscribe for the real data
Number of persons purchased
Plot placeholder
Mock data
Subscribe for the real data
Number of purchases
Plot placeholder
Mock data
Subscribe for the real data
Refill frequency
Plot placeholder
Mock data
Subscribe for the real data
Price per prescription (USD)
Plot placeholder
Mock data
Subscribe for the real data
Tabular view
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Plot placeholder
Mock data
Subscribe for the real data
Additional graphs summarizing 14,929 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Plot placeholder
Mock data
Subscribe for the real data
13,841 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use